Italia markets close in 4 hours 54 minutes

Madrigal Pharmaceuticals, Inc. (0JXI.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
274,39-9,16 (-3,23%)
In data: 02:47PM BST. Mercato aperto.
Schermo intero
Chiusura precedente283,55
Aperto0,00
Denaro0,00 x 0
Domanda0,00 x 0
Min-Max giorno0,00 - 0,00
Intervallo di 52 settimane
Volume328
Media Volume201
Capitalizzazione4,222B
Beta (mensile su 5 anni)-0,41
Rapporto PE (ttm)N/D
EPS (ttm)-14,65
Prossima data utili06 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    CONSHOHOCKEN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to seven new employees with a grant date of October 10, 2023 as equity inducement awards outside of the Company’s Amended 2015 Stock Plan under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accord

  • GlobeNewswire

    Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

    CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 1,248,098 shares of its common stock at a public offering price of $151.69 per share, and, to certain investors, pre-funded warrants to purchase 2,048,098 shares of common stock at a price of $151.6899 per pre-funded war

  • GlobeNewswire

    Madrigal Pharmaceuticals Announces Proposed Public Offering

    CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it has commenced an underwritten public offering of $500 million in shares of its common stock and, to certain investors, pre-funded warrants to purchase common stock. The purchase price of each pre-funded warrant will equal the price per share at which shares of co